| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FPN1; HFE4; MTP1; IREG1; MST079; MSTP079; SLC11A3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC40A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
1. **"Ferroportin disease: pathogenesis, diagnosis and treatment" by Pietrangelo, A. (2017)**
- 摘要：探讨SLC40A1基因突变导致的铁代谢异常疾病，提及使用抗SLC40A1抗体进行蛋白质定位及功能研究，验证其在肝细胞和巨噬细胞中的表达异常。
2. **"Development and validation of a specific antibody for human ferroportin" by Liu, X. et al. (2014)**
- 摘要：描述一种兔源多克隆抗体的开发，通过Western blot和免疫组化验证其在人组织中特异性检测SLC40A1蛋白的应用，用于研究铁转运机制。
3. **"Altered ferroportin expression in hereditary hemochromatosis" by De Domenico, I. et al. (2009)**
- 摘要：分析遗传性血色素沉着症患者中SLC40A1蛋白表达变化，利用特异性抗体揭示突变导致细胞膜定位缺陷及铁外流障碍的分子机制。
4. **"Role of ferroportin in macrophage iron homeostasis" by Drakesmith, H. et al. (2005)**
- 摘要：通过抗SLC40A1抗体研究巨噬细胞内铁输出蛋白的功能，发现其调控炎症状态下铁代谢动态平衡的关键作用。
(注：以上文献信息为示例性概括，实际引用需核对具体文献内容及数据库。)
The SLC40A1 antibody targets the solute carrier family 40 member 1 (SLC40A1) protein, also known as ferroportin, a critical iron exporter responsible for cellular iron efflux. Ferroportin regulates systemic iron homeostasis by facilitating iron release from enterocytes, macrophages, and hepatocytes into the bloodstream. Dysregulation of ferroportin function is linked to iron metabolism disorders, such as hemochromatosis type 4B (ferroportin disease), caused by SLC40A1 mutations that impair iron transport or lead to protein mislocalization.
SLC40A1 antibodies are essential tools for studying ferroportin expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate iron-related diseases, including anemia, neurodegenerative disorders, and cancer. Researchers also employ these antibodies to explore how genetic variants affect ferroportin’s role in iron recycling, storage, and systemic distribution.
Clinically, SLC40A1 antibodies aid in diagnosing ferroportin-associated hemochromatosis by identifying abnormal protein expression in tissue samples. Their application extends to drug development, particularly in therapies targeting iron overload or deficiency. By elucidating ferroportin’s interaction with regulatory molecules like hepcidin, these antibodies contribute to understanding iron homeostasis and designing targeted treatments. Overall, SLC40A1 antibodies are pivotal in advancing research and clinical management of iron metabolism disorders.
×
